Ab­b­Vie’s first post-merg­er Al­ler­gan drug pitch strikes out with the FDA as reg­u­la­tors turn thumbs down on Lu­cen­tis chal­lenger

Al­ler­gan has re­ceived its first FDA de­ci­sion since of­fi­cial­ly be­com­ing a part of Ab­b­Vie. And it’s bad news.

Reg­u­la­tors have spurned abic­i­par, the neo­vas­cu­lar age …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER